ArticleTranslational lung cancer research2026
Efficacy of ipilimumab plus nivolumab with or without chemotherapy according to baseline tumor size: a multicenter retrospective study.
Article in Translational lung cancer research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
20 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Ipilimumab plus nivolumab (I-N) with or without chemotherapy is an established first-line treatment for advanced non-small cell lung cancer (NSCLC). For patients with a large baseline tumor size (BTS), chemotherapy combined with immune checkpoint inhibitors (ICIs) has shown better outcomes compared with ICI monotherapy. However, the specific radiographic size criteria for determining whether to prioritize the CheckMate227 or CheckMate9LA regimen are undefined. Therefore, we evaluated how BTS impacts the efficacy of I-N-based therapy in our cohort. Methods: This multicenter retrospective study was conducted across 19 institutions in Japan. Adult patients with advanced NSCLC with programmed death-ligand 1 (PD-L1) tumor proportion score (TPS) 1-49% who received I-N-based therapy as first-line systemic treatment between January 2018 and March 2022 were included. We excluded patients with Results: A total of 87 patients were included: 25 in the I-N group and 62 in the I-N-chemo group. Among patients with BTS ≥50 mm, median progression-free survival (PFS) was 4.0 months [95% confidence interval (CI): 0.7-6.7] in the I-N group and 5.5 months (95% CI: 3.4-8.1) in the I-N-chemo group (P=0.03). Median overall survival (OS) was 8.3 months (95% CI: 1.0-10.7) for I-N and 17.7 months (95% CI: 10.9-not reached) for I-N-chemo (P=0.005). Among patients with BTS <50 mm, there were no statistically significant differences in PFS or OS between the I-N and I-N-chemo groups. Conclusions: Our findings suggest that I-N combined with chemotherapy may be effective treatment for NSCLC patients with a high tumor burden (BTS ≥50 mm). However, given the retrospective nature of this study and the limited subgroup sample sizes, these results should be interpreted with caution.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.